A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients With Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101
Latest Information Update: 25 Oct 2022
At a glance
- Drugs Etrinabdione (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Emerald Health Pharmaceuticals
- 19 Oct 2022 Status changed from recruiting to suspended.
- 11 Jan 2022 Planned End Date changed from 1 Sep 2023 to 1 Apr 2024.
- 11 Jan 2022 Planned primary completion date changed from 1 Jun 2023 to 1 Dec 2023.